BillionToOne, Inc.

424B4 priced

Price $60.00 · 4,551,100 shares · Gross proceeds $273,066,000

BillionToOne, Inc. is conducting an initial public offering (IPO) of 4,551,100 shares of Class A common stock at $60.00 per share, totaling $273.1 million. The company will list on the Nasdaq Global Select Market under the symbol 'BLLN.' Following the offering, the company will have two classes of stock: Class A (1 vote per share) and Class B (15 votes per share, convertible to Class A). The co-founders, Oguzhan Atay (CEO) and David Tsao (CTO), will collectively own 63.9% of voting power through their 100% ownership of Class B stock. The company is an emerging growth company, leveraging reduced reporting requirements. The underwriters have an option to purchase additional shares and a directed share program for insiders.

CERT inactive

BillionToOne, Inc. is registering its Class A common stock on The Nasdaq Stock Market LLC. The filing references the company's prospectus from its S-1 registration statement, indicating preparation for a public offering. The current CERT filing likely relates to an update or amendment of previous securities registration details.

8-A12B effective

BillionToOne, Inc. is registering its Class A common stock for listing on the Nasdaq Stock Market LLC under Form 8-A12B, referencing its prior S-1/A registration statement. The filing confirms the company's intent to list its shares, with no new details provided beyond incorporating the earlier prospectus. The company, an emerging growth company, has not yet disclosed specific risk factors in this filing but references its earlier S-1/A document for risk disclosures.

S-1/A amended

Price $52.00 · Range $49.00 to $55.00 · 3,846,000 shares

BillionToOne, Inc. is conducting an initial public offering (IPO) of 3,846,000 Class A common shares, with an expected price range of $49.00 to $55.00 per share. The offering follows a 84% year-over-year revenue growth and aims to list on Nasdaq under the symbol 'BLLN.' The company emphasizes its proprietary diagnostic technology for early disease detection, with $265M+ annualized revenue run-rate and 65% gross profit margin. Post-IPO, the company will have dual-class stock structure, with founders retaining significant voting control via Class B shares. The filing includes detailed financial metrics, underwriting terms, and risk factors related to regulatory, competitive, and technological challenges.

S-1 filed

BillionToOne, Inc. is conducting an initial public offering (IPO) of its Class A common stock, aiming to raise capital for growth and expansion. The company specializes in advanced diagnostic technologies, focusing on early disease detection through innovative molecular analysis. The IPO follows a confidential DRS/A filing, with key financial metrics including $265M+ annualized revenue, 84-86% YoY revenue growth, and a $100B US market opportunity. The offering includes Class A and Class B shares, with Class B holders retaining significant voting control. The company is an emerging growth company and has elected reduced reporting requirements.

DRS/A amended

BillionToOne, Inc. is preparing for its initial public offering (IPO) of Class A common stock, with an expected price range of $ to $ per share. The company aims to list on the Nasdaq Global Market under the symbol 'BLLN.' Following the offering, it will maintain two classes of stock, with Class B shares (held by Co-Founders Oguzhan Atay and David Tsao) retaining 10 votes per share. The IPO is contingent on Nasdaq approval, and the Co-Founders will retain significant voting control. The company emphasizes its emerging growth status, reduced reporting requirements, and a directed share program for employees. Key financial metrics include $265M+ annualized revenue run-rate, 86% YOY revenue growth, and 65% gross margin.

DRS/A amended

BillionToOne, Inc. is conducting an initial public offering (IPO) of Class A common stock, aiming to list on the Nasdaq Global Market under the symbol 'BLLN'. The company, an emerging growth company, specializes in precision diagnostics using advanced technology to detect diseases at the molecular level. The offering includes details on share pricing, underwriters, and the structure of voting rights between Class A and Class B shares. The filing emphasizes the company's market opportunity, revenue growth, and risk factors associated with the IPO.

DRS filed

BillionToOne, Inc. is conducting an initial public offering (IPO) of Class A common stock, transitioning from an R&D-focused entity to a commercial organization. The company's smNGS platform enables ultra-sensitive detection of genetic targets, powering prenatal tests like UNITY and oncology liquid biopsies Northstar Select and Northstar Response. The IPO is contingent on Nasdaq listing approval, with proceeds intended for growth, R&D, and working capital. The company emphasizes its technological leadership in molecular diagnostics but highlights risks related to competition, regulatory hurdles, and reliance on key personnel.